NCT05707520

Long-term Benefit of MPA in Liver Transplantation

Clinical Evaluation of the Long-term Benefit of Enteric-coated Mycophenolate (MPAs) After Liver Transplantation

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Third Affiliated Hospital, Sun Yat-Sen University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

MPA drugs are antiproliferative immunosuppressants and are widely used in solid organ transplantation. MPA drugs do not affect the recipient's kidney function and do not cause metabolic abnormalities and other problems. Intestinal solvent-based MPA drugs are widely used in clinical practice by improving the dosage form, reducing the irritation of MPA to the mucosa of the digestive tract, improving the tolerability of patients and maintaining a sufficient amount of MPA. However, data on the use/long-term use of intestinal solvent-based MPAs in liver transplant recipients are lacking. The study aims to evaluate the long-term benefits of enteric-coated mycophenolic acid in liver transplant recipients.

Conditions

• Liver Transplant Rejection
• Immunosuppressant Adverse Reaction

Interventions

Type	Name	Description
DRUG	enteric-coated mycophenolate (MPAs)	Immunosuppression protocol with enteric-coated mycophenolate sodium
DRUG	None MPA	Immunosuppression protocol without enteric-coated mycophenolate sodium

Timeline

• Start date: 2022-12-04
• Primary completion: 2023-06-30
• Completion: 2023-09-30
• First posted: 2023-02-01
• Last updated: 2023-02-01

Locations

1 site across 1 country: China